AxoGen内幕人士卖出超过15万股, 价值454K美元 — 12月9日为1.92M美元, AxoGen insiders sold over 150,000 shares worth $454K–$1.92M on Dec. 9, despite strong earnings.

2025年12月9日,包括CEO Michael Dale、董事Joseph Tyndall、董事Paul Thomas和CFO Lindsey Marie Hartley在内的多家AxoGen公司内幕人士在2025年12月9日出售了总额超过150 000股的股份,其收益从454 000美元到192万美元不等。 On December 9, 2025, multiple AxoGen insiders, including CEO Michael Dale, Director Joseph Tyndall, Director Paul Thomas, and CFO Lindsey Marie Hartley, sold shares totaling over 150,000 shares combined, with proceeds ranging from $454,000 to $1.92 million. 这些交易在证交会档案中披露,大大减少了他们的股份。 The transactions, disclosed in SEC filings, reduced their stakes significantly. AxoGen公司在10月29日报告说,第四季度收入强劲,12美元EPS和6 008万美元收入超过估计数,尽管该公司仍然无利可图,净利润为负数,股本回报率为负数。 AxoGen reported strong fourth-quarter earnings on October 29, with $0.12 EPS and $60.08 million in revenue, exceeding estimates, though the company remains unprofitable with negative net margin and return on equity. 12月10日,库存关闭30.01美元,减少0.60美元,交易量略低于平均数。 The stock closed at $30.01 on December 10, down $0.60, with trading volume slightly below average. 分析师维持“机动购买”共识评级,平均价格目标是35.56美元。 Analysts maintain a "Moderate Buy" consensus rating and an average price target of $35.56.